You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Perspectives in Lung Cancer 2021: Management of SCLC

  • Authors: Kristin Higgins, MD; Taofeek Owonikoko, MD, PhD; Ticiana Leal, MD
  • CME / ABIM MOC / CE Released: 9/22/2021
  • Valid for credit through: 9/22/2022
Start Activity

Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, pathologists, radiologists, surgeons, primary care physicians, critical care specialists, internal medicine specialists, emergency medicine physicians, nurses/nurse practitioners, physician assistants, and pharmacists involved in the care of patients with or at risk for lung cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or malignant pleural mesothelioma (MPM).

The goal of this activity is to improve clinicians’ understanding of the therapeutic management of patients with SCLC. 

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data evaluating regimens used to treat patients with SCLC
    • Role of radiation therapy in the management of patients with SCLC
  • Have greater competence related to
    • Tailoring therapy across first-line and second-line settings for patients with SCLC
  • Demonstrate greater confidence in their ability to
    • Understand the clinical implications of the available evidence for therapies in the treatment paradigm of SCLC


As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

All of the relevant financial relationships listed for these individuals have been mitigated.


  • Kristin Higgins, MD

    Associate Professor
    Department of Radiation Oncology
    Emory University School of Medicine
    Winship Cancer Institute
    Atlanta, Georgia

    The opinions expressed are those of Dr Higgins and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Higgins’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.


    Disclosure: Kristin Higgins, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca
    Received grants for clinical research from: Reflexion Medical

  • Taofeek Owonikoko, MD, PhD

    Chief, Division of Hematology/Oncology
    Associate Director for Translational Research and Co-Leader Cancer Therapeutics Program
    UPMC Hillman Cancer Center
    University of Pittsburgh School of Medicine
    Pittsburgh, Pennsylvania


    Disclosure: Taofeek Owonikoko, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; Bristol Myers Squibb; EMD Serono; Ipsen; Jazz Pharmaceuticals; Merck; Roche; Takeda
    Owns stock, stock options, or bonds from: Cambium Oncology

  • Ticiana Leal, MD

    Associate Professor of Medicine
    Thoracic Oncology Program Leader
    Division of Hematology/Oncology
    University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin


    Disclosure: Ticiana Leal, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; Bayer; Genentech; Janssen; Jazz Pharmaceuticals; Blueprint; Boehringer Ingelheim; EMD Serono; Genentech; Lilly; Mirati


  • Megan Cannon, PhD

    Medical Education Director, WebMD Global, LLC


    Disclosure: Megan Cannon, PhD, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Perspectives in Lung Cancer 2021: Management of SCLC

Authors: Kristin Higgins, MD; Taofeek Owonikoko, MD, PhD; Ticiana Leal, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 9/22/2021

Valid for credit through: 9/22/2022


BM = brain metastases
BP = blood pressure
CDK = cyclin-dependent kinase
CNS = central nervous system
CR = complete response
CT = computed tomography
CTFI = chemotherapy-free interval 
ECOG = Eastern Cooperative Oncology Group
ES = extensive-stage   
HA = hippocampus avoidance
IMRT = intensity-modulated radiation therapy
IO = immuno-oncology
ITT = intention-to treat
MPM = malignant pleural mesothelioma
MRI = magnetic resonance imaging
NCCN = National Comprehensive Cancer Network 
NSCLC = non-small cell lung cancer
ORR = overall response rate 
OS = overall survival
PCI = prophylactic cranial irradiation
PD = progressive disease
PD-L1 = programmed death-ligand 1 
PET = positron emission tomography 
PFS = progression-free survival 
PR = partial response
PS = performance status
RCT = randomized controlled trial
RECIST = Response Evaluation Criteria in Solid Tumors
RML = right middle lobe
RR = respiratory rate
RT = radiotherapy
SCLC = small-cell lung cancer 
SD = stable disease
SIADH = syndrome of inappropriate antidiuretic hormone secretion 
TFI = treatment-free interval
TRT = thoracic radiotherapy
WBRT = whole brain radiotherapy

« Return to: Perspectives in Lung Cancer 2021: Management of SCLC
  • Print